EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer

Marc Creixell, Scott D Taylor, Jacqueline Gerritsen, Mingxuan Jiang, Song Yi Bae, Teresa Augustin, Michelle Loui, Carmen Boixo, Saki Minamino, Victoria Gong, Pau Creixell, Forest M White und 1 weitere

Cell Reports · 2026-07 · 45 (7) · 117717

DOI: 10.1016/j.celrep.2026.117717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026-07. Verfasst von Marc Creixell und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of C…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Erlotinib Hydrochloride, Lung Neoplasms, Proto-Oncogene Proteins. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health Office of Extramural Research, The Mark Foundation for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmErlotinib HydrochlorideLung NeoplasmsProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAdaptor Proteins, Signal TransducingMutationTranscription FactorsFocal Adhesion Kinase 1PhosphoproteinsHumansErbB ReceptorsSignal TransductionPhosphorylationCell Line, TumorAxl Receptor Tyrosine KinaseYAP-Signaling Proteins

Stichwörter der Autor:innen

AXLCP: cancerEGFRLUADcomputational modelingdrug resistancekinase biologysystems biology

Substanzen

Erlotinib HydrochlorideErbB ReceptorsProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAxl Receptor Tyrosine KinaseAdaptor Proteins, Signal TransducingYAP-Signaling ProteinsYAP1 protein, humanTranscription FactorsFocal Adhesion Kinase 1

Autor:innen und Institutionen

  • Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Cen…
  • Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 2RE, UK.
  • Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address…

Förderung

  • NCI NIH HHS
  • National Institutes of Health Office of Extramural Research
  • The Mark Foundation for Cancer Research

Zitieren

APA

Creixell, M., Taylor, S. D., Gerritsen, J., Jiang, M., Bae, S. Y., Augustin, T., Loui, M., Boixo, C., Minamino, S., Gong, V., Creixell, P., White, F. M., & Meyer, A. S. (2026). AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer. Cell Reports, 45(7), 117717. https://doi.org/10.1016/j.celrep.2026.117717

Vancouver

Creixell M, Taylor SD, Gerritsen J, Jiang M, Bae SY, Augustin T, et al. AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer. Cell Reports. 2026;45(7):117717. doi:10.1016/j.celrep.2026.117717

BibTeX
@article{Creixell2026,
  author = {Creixell, Marc and Taylor, Scott D and Gerritsen, Jacqueline and Jiang, Mingxuan and Bae, Song Yi and Augustin, Teresa and Loui, Michelle and Boixo, Carmen and Minamino, Saki and Gong, Victoria and Creixell, Pau and White, Forest M and Meyer, Aaron S},
  title = {AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer},
  journal = {Cell Reports},
  year = {2026},
  volume = {45},
  number = {7},
  pages = {117717},
  doi = {10.1016/j.celrep.2026.117717}
}
Kostenlos starten →